In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

  • Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00493-18. doi: 10.1128/AAC.00493-18.
Carolyn Shoen  1 ,  Michelle DeStefano  2 ,  Barry Hafkin  3 ,  Michael Cynamon  1  4
Affiliations
  • 1. Central New York Research Corporation, Syracuse, New York, USA [email protected] [email protected].
  • 2. Central New York Research Corporation, Syracuse, New York, USA.
  • 3. MicuRx Pharmaceuticals, Hayward, California, USA.
  • 4. Veterans Affairs Medical Center, Syracuse, New York, USA.
PMID: 29784848 DOI: 10.1128/AAC.00493-18
Abstract

The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro MRX-I and LZD were subsequently studied in BALB/c mice infected intranasally with M. tuberculosis Erdman. MRX-I and LZD at 100 mg/kg significantly reduced the Bacterial load in lungs compared to the untreated early and late controls.

Keywords
Mycobacterium tuberculosis; in vitro; mouse model; oxazolidinones.
Products